Forbes April 8, 2024
Precision medicine’s promise is selecting the right drug for the appropriate person in a timely manner. But besides cancer, in most disease areas trial-and-error prescribing of therapeutics continues to reign, even when tests are available to differentiate between responders and non-responders and those who are susceptible or not to adverse events. This can lead to substantial waste of healthcare resources. Science still outpaces commercialization of many diagnostic tests. Changes to the reimbursement model to align price with value could offer a remedy.
Genomic tests which detect the presence of certain biomarkers can personalize therapy selection, diagnose specific disease types and predict level of response. A diagnostic is said to have clinical utility if the test leads to changes in the...
Today's Sponsors
Today's Sponsor